Dr Christopher Ting is currently the CEO of Pathology Asia Holdings (Singapore), the largest network of laboratories in Southeast Asia. He is the founder and first CEO of Quantum Diagnostics (Malaysia). He is also a co-founder of Biomark (Singapore). He was the CEO of Innovative Diagnostics (Singapore and HK). He has served as CEO of Timberland Medical Center (Malaysia).
While previously with Healthscope Ltd. (Australia), he oversaw Gribbles Pathology (Malaysia) and Quest Laboratories (Singapore). He was previously with the Economic Development Board of Singapore, specifically the Biomedical Sciences Group. He has participated in the Malaysian government’s healthcare NKEA initiative.
He obtained his medical degree from the University of Melbourne (Australia) and completed his MBA at the Melbourne Business School (Australia).